中华皮肤科杂志 ›› 2012, Vol. 45 ›› Issue (5): 352-354.

• 研究报道 • 上一篇    下一篇

E型沙眼衣原体临床株热休克蛋白60含量变化及传代衣原体培养与疗效的关系

尤聪1,刘原君1,姚卫锋1,王梅2,江勇3,邵丽丽1,刘全忠1   

  1. 1. 天津医科大学总医院皮肤性病科
    2. 天津医科大学总医院皮肤科
    3. 天津医科大学第二医院皮肤性病科
  • 收稿日期:2011-06-07 修回日期:2011-07-24 出版日期:2012-05-15 发布日期:2012-05-03
  • 通讯作者: 刘全忠 E-mail:liuquanzhong@medmail.com.cn
  • 基金资助:

    国家自然科学基金项目

Changes of heat shock protein 60 levels during subcultures of clinical isolates of Chlamydia trachomatis serotype E and their relationship with treatment outcomes of patients

  • Received:2011-06-07 Revised:2011-07-24 Online:2012-05-15 Published:2012-05-03
  • Contact: quanzhong liu E-mail:liuquanzhong@medmail.com.cn

PDF

28

赞

摘要：

目的 探讨E型标准株和细胞培养成功的沙眼衣原体E型临床株随着传代次数的增加其热休克蛋白60（HSP60）含量的改变。方法 经McCoy细胞培养法检测出的40例E型沙眼衣原体临床株，分为首次传代出现和未出现包涵体两组，通过RT-PCR方法检测1 ~ 4次传代的HSP60含量，?字2检验其与对应患者疗效的关系。结果 经细胞培养成功的E型沙眼衣原体临床株传代未出现包涵体时其HSP60含量较出现包涵体时高（P ＜ 0.05）。18例首次传代出现包涵体的标本1 ~ 4次传代HSP60/16SrRNA分别为0.38 ± 0.06、0.39 ± 0.03、0.38 ± 0.04、0.39 ± 0.03；12例2次传代出现包涵体的标本1 ~ 4次传代HSP60/16SrRNA分别为1.18 ± 0.10、0.28 ± 0.06、0.30 ± 0.03、0.29 ± 0.05；10例3次传代出现包涵体的标本1 ~ 4次传代HSP60/16SrRNA分别为1.20 ± 0.04、1.20 ± 0.04、0.28 ± 0.04、0.28 ± 0.05。患者疗效对1次传代是否出现包涵体有影响，20例治疗失败患者16例1次传代未出现包涵体，1个疗程治疗后转阴患者20例中14例在1次传代出现包涵体。结论 80%治疗失败患者1次传代未见包涵体，临床株传代培养未出现包涵体时沙眼衣原体可能处于持续感染状态，其ＣＨＳＰ６０合成增加，临床采集的衣原体标本至少应进行3次盲传以避免漏检。

关键词: 持续性感染

Abstract:

Objective To detect the changes of heat shock protein 60 （HSP60） during the subcultures of standard and clinical strains of Chlamydia trachomatis （Ct）, and to determine if the absence of chlamydial inclusions is associated with the persistent infection of Ct. Methods A total of 40 Ct strains isolated by cell culture from patients were included in this study and classified into 2 groups according to whether inclusions appeared after initial culture. Reverse transcription PCR was conducted to quantify the levels of HSP60 in specimens containing Ct after 1－4 subcultures. Chi-squared test was performed to analyze the relationship between the levels of HSP60 and treatment outcomes of patients. Results The levels of HSP60 in clinical specimens containing Ct serovar E were significantly higher in subcultures prior to the appearance of inclusions than in subcultures with the appearance of inclusions （P < 0.05）. The ratio of HSP60:16S rRNA mRNA expression after the first, second, third, fourth passage was 0.38 ± 0.06, 0.39 ± 0.03, 0.38 ± 0.04 and 0.39 ± 0.03 respectively in 18 specimens with inclusions appearing after the initial culture, 1.18 ± 0.10, 0.28 ± 0.06, 0.30 ± 0.03 and 0.29 ± 0.05 respectively in 12 specimens with inclusions appearing after the second culture, 1.20 ± 0.04, 1.20 ± 0.04, 0.28 ± 0.04 and 0.28 ± 0.05 in 10 specimens with inclusions appearing after the third culture. Whether inclusions appeared after the initial culture was associated with the treatment outcome of patients. Inclusions were undetected after the initial culture in 16 of 20 specimens from patients with poor response to treatment, but observed in 14 of 20 specimens from patients who tested negative for Ct after one course of treatment. Conclusions It is implicated that no inclusions form after the initial culture in 80% of specimens from patients experiencing treatment failure. The Ct strains whose inclusions do not form after passages may be in a persistent state, and the expression of HSP60 is high in these strains. Specimens should be subjected to at least 3 blind passages to avoid missed diagnosis of Ct infection.

Key words: persistent infection